Apremilast for moderate to severe psoriasis
Part of Skin clinical trials.
This study tests whether apremilast (a pill) safely and effectively treats moderate-to-severe psoriasis. If you join, you will receive the medication and be monitored by the study team to see how well it works for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years of age or older.
- You have had moderate to severe psoriasis for at least 6 months, with a PASI score between 5 and 10.
- You have not taken apremilast before and are not allergic to it.
- You are not pregnant or breastfeeding, and agree to use reliable birth control during the study.
- You do not have severe kidney disease that requires dialysis, and you are not taking certain medications that could interfere.
- You are able to attend all study visits and follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cream form of apremilast, a medicine usually taken as a pill, for people with plaque psoriasis covering less than 10% of their body. The goal is to see if the cream is safe and effective in reducing psoriasis symptoms.
This study compares two oral medications, methotrexate and apremilast, to see which works better at reducing itching in people with psoriasis. You might join to help find a more effective way to relieve itch.
This trial tests a new medication, CBP-0276, to see if it improves psoriasis symptoms and quality of life. It is for people with moderate to severe plaque psoriasis who might need stronger treatment.
This trial tests an experimental pill that may help clear psoriasis plaques. It is for people whose current topical treatments (creams or ointments) are not working well enough or cause side effects.
This trial tests a new medication (HS-10374) taken by mouth to see if it is safe and effective for people with moderate to severe plaque psoriasis. It might help reduce the redness, scaling, and thickness of psoriasis plaques.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.